abs102.txt	purpose		lung	cancer	is	the	leading	cause	of	cancer-related	death		non-small	celllung	cancer	(nsclc)	accounts	for	85%	of	all	lung	cancers	and	over	60%	expresswild-type	egfr	(wtegfr)		however		egfr	tyrosine	kinase	inhibitors	(tkis)	havelimited	effect	in	most	patients	with	wtegfr	tumors		we	previously	identifiedmertk	tyrosine	kinase	as	a	potential	therapeutic	target	in	nsclc	and	developedmrx-2843		a	novel	mertk-selective	inhibitor	with	favorable	properties	forclinical	translation		the	goal	of	this	study	was	to	determine	whether	mertk	andegfr	inhibitor	combination	therapy	could	provide	antitumor	efficacy	againstwtegfr	nsclc	experimental	design		an	unbiased	screen	of	378	kinase	inhibitors	wasconducted	to	identify	synergistic	interactions	with	mrx-2843	and	biochemical	andtherapeutic	effects	were	determined	in	vitro	and	in	vivo	results		numerousirreversible	egfr	tkis		including	co-1686	and	osimertinib		synergized	withmrx-2843	to	inhibit	wtegfr	nsclc	cell	expansion		irrespective	of	driver	oncogenestatus		co-1686	and	mrx-2843	combination	therapy	inhibited	mertk		wtegfr		anderbb2/erbb3	and	decreased	downstream	pi3k-akt		mapk-erk		and	aurora	kinase	(aurk)signaling	more	effectively	than	single	agents		inhibition	of	pi3k		akt	or	aurk	but	not	mek		synergized	with	co-1686	to	inhibit	tumor	cell	expansion		suggestingtheir	roles	as	key	redundant	resistance	pathways		treatment	with	mrx-2843	andco-1686	or	osimertinib	prevented	xenograft	growth	while	single	agents	had	limitedeffect		tumor	growth	inhibition	was	durable	even	after	treatment	with	combinationtherapy	was	stopped	conclusions		our	data	support	the	application	of	mrx-2843	incombination	with	an	irreversible	egfr	tki	as	a	novel	strategy	for	treatment	ofpatients	with	wtegfr	nsclc		clin	cancer	res		1-13		Â©2018	aacr	
